An intermediate-purity factor VIII concentrate supports platelet adhesion under flow conditions

Haemophilia

Volumn 3, Issue 1, 1997, Pages 14-20

  Aznar Salatti, J ^a,d   Escolar, G ^b   Arnau, C ^a   Carretero, M ^b   White, J G ^c   Garcia Barbal J ^a   Castillo, R ^b   Ordinas, A ^b  

^a Dep Invest y Desarrollo   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF MINNESOTA   (United States)

^d CENTEON SA Ronda Gen Mitre   (Spain)

Author keywords

FVIII concentrate; Haemate P; Haemostasis; Platelet adhesion; Von Willebrand disease

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; RISTOCETIN; VON WILLEBRAND FACTOR;

AORTA; ARTICLE; BLEEDING TIME; CRYOPRECIPITATE; HEMOSTASIS; HUMAN; HUMAN CELL; IMMUNOELECTRON MICROSCOPY; PRIORITY JOURNAL; RABBIT; SUBENDOTHELIUM; THROMBOCYTE ADHESION; THROMBOCYTE MEMBRANE; VON WILLEBRAND DISEASE;

EID: 0031027126     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1997.00067.x     Document Type: Article

References (33)

1. Weiss HJ, Turitto VT, Baumgartner HR. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear dependent decrease of adhesion in von Willebrand's disease and the Bernard-Soulier syndrome. J Lab Clin Med, 1978; 92: 750-64.
2. Bolhuis PA, Sakariassen KS, Sander HJ, Bourma BN, Sixma JJ. Binding of factor VIII-von Willebrand factor to human arterial subendothelium precedes increased platelet adhesion and enhances platelet spreading. J Lab Clin Med, 1981; 97: 568-76.
3. Stel HV, Sakariassen KS, de Groot PG, van Mourik JA, Sixma JJ. Von Willebrand factor in the vessel wall mediates platelet adherence. Blood, 1985; 65: 85-90.
4. Holmberg L, Nilsson IM. Von Willebrand's disease. Eur J Haematol, 1992; 48: 127-41.
5. Mannucci PM, Moia M, Rebulla P, Altieri D, Monteagudo J, Castillo R. Correction of the bleeding time in treated patients with severe von Willebrand disease is not solely dependent on the normal multimeric structure of plasma von Willebrand factor. Am J Hematol, 1987; 25: 55-65.
6. Castillo R, Escolar G, Monteagudo J, et al. Role for platelet von Willebrand factor in supporting platelet-vessel wall interactions in von Willebrand disease. Am J Hematol, 1989; 31: 153-8.
7. Nilsson IM, Hedner U. Characteristics of various factor VIII concentrates used in treatment of hemophilia. Br J Haemat 1977; 37: 543-57.
8. Blatt PM, Brinkhous KM, Culp HR, Krauss JS, Roberts HR. Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding time factor and ristocetincofactor activities. J Am Med Ass, 1976; 236: 2770-2.
9. Nilsson IM, Borge L, Gunnarsson M, Kristoffersson AC. Factor VIII related activities in concentrates. Scand J Haematol 1984; 33 (Suppl 42): 157-72.
10. Fricke WA, Yu MW. Characterization of von Willebrand factor in factor VIII concentrates. Am J Hematol, 1989; 31: 41-5.
11. Lawrie AS, Harrison P, Armstrong AL, Wilbourn BR, Dalton RG, Savidge GF. Comparison of the in vitro characteristics of von Willebrand factor in British and commercial factor VIII concentrates. Br J Haematol, 1989; 73: 100-4.
12. Sixma JJ, Sakariassen KS, Beeser-Visser NH, Ottenhof-Rovers M, Bolhuis PA. Adhesion of platelets to human artery subendothelium: effect of factor VIII-von Willebrand factor of various multimeric composition. Blood, 1984; 63: 128-39.
13. Sakariassen KS, Muggli R, Baumgartner HR. Measurements of platelet interaction with components of the vessel wall in flowing blood. Methods Enzymol, 1989; 169: 37-70.
14. Sakariassen KS, Roald HE, Aznar Salatti J. Ex vivo models for studying thrombosis: Special emphasis on shear rate dependent blood-collagen interactions. In Hwang N, Tejeira R, Turitto VT, eds. Advances in Cardiovascular Engineering. New York: Plenum Press, 1992; 151-74.
15. Escolar G, Mazzara R, Castillo R, Ordinas A. The role of Baumgartner technique in transfusion medicine: research and clinical applications. Transfusion, 1994; 34: 542-9.
16. American Association of Blood Banks. The Technical Manual of the American Association of Blood Banks, 9th edn. Philadelphia: JB Lippincott 1985.
17. Gerrard JM, Phillips DR, Rao GH, et al. Biochemical studies of two patients with the gray platelet syndrome. Selective deficiency of platelet alpha granules. J Clin Invest, 1980; 66: 102-9.
18. Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc Res, 1973; 5: 175-9.
19. Escolar G, Bastida E, Ordinas A, Castillo R. Interaction of platelets with subendothelium in humans treated with aspirin and dipyridamole alone or in combination. Thromb Res, 1985; 40: 419-24.
20. Escolar G, Garrido M, Aznar-Salatti J, Ordinas A, Bastida E. Comparison between human umbilical artery and rabbit abdominal aorta as substrata for platelet adhesion and platelet thrombus formation under flow conditions. Blood vessels, 1991; 28: 520-31.
21. Escolar G, Bastida E, Ordinas A, Castillo R. Development of a computer program to analyze the parameters of platelet-vessel wall interaction. Hemostasis, 1986; 16: 8-14.
22. Escolar G, White JG. Organization of von willebrand factor on surface-activated platelets. Arterioscl Thromb, 1993; 13: 1852-8.
23. Hardisty R, MacPherson C. A one stage factor VIII assay and its use on venous and capillary plasma. Thromb Diath Haemorrahgica, 1962; 7: 215-28.
24. Zuzel M, Nilsson IM, Alberg M.A. A method for measuring plasma ristocetin cofactor activity. Normal distribution and stability during storage. Thromb Res 1978; 12: 745-54.
25. Ingerslev J. A sensitive ELISA for von Willebrand factor (vWF:Ag). Scand J Clin Lab Invest, 1985; 45: 17-26.
26. Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood, 1981; 57: 1140-3.
27. Pereira A, Monteagudo J, Bono A, López-Guillermo A, Ordinas A. Effect of splenectomy on von Willebrand factor multimeric structure in thrombotic thrombocytopenic purpura refractory to plasma exchange. Blood Coag Fibrinol, 1993; 4: 783-6.
28. Hollander M, Wolfe DA. The two way lay-out. In: Non Parametric Statistical Methods. Wiley Series in probability and mathematical statistics. New York: John Willey & Sons, 1973; 138-84.
29. Takahashi H, Tatewaki W, Nagayama R, et al. Heat-treated factor VIII/von Willebrand factor concentrate in platelet-type von Willebrand's disease. Haemostasis, 1987; 17: 353-60.
30. Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood, 1992; 79: 3130-7.
31. Escolar G, Monteagudo J, Villamor N, Garrido M, Castillo R, Ordinas A. Ristocetin induces platelet aggregation: a morphological demonstration. Br J Haematol, 1988; 69: 379-86.
32. Mazurier C, De Romeuf C, Parquet-Gernez A, Goudemand M. In vitro and in vivo characterization of a high-purity, solvent/detergent factor VIII concentrate: evidence for its therapeutic efficacy in von Willebrand disease. Eur J Haematol, 1989; 43: 7-14.
33. Sakariassen KS, Baumgartner HR. Axial dependence of platelet-collagen interactions in flowing blood. Upstream thrombus growth impairs downstream platelet adhesion. Arteriosclerosis, 1989; 9: 33-42.